Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03761615 · ClinicalTrials.gov registry record
Longitudinal Observation of Insulin Requirements and Sensor Use in Pregnancy
A clinical trial, sponsored by Sansum Diabetes Research Institute.
- Completed
- Registry status
- 25
- Enrollment target
NCT03761615: Completed study, sponsored by Sansum Diabetes Research Institute.
NCT03761615 is a clinical trial that has completed, run by Sansum Diabetes Research Institute. The registered enrollment target is 25 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03761615 has completed, sponsored by Sansum Diabetes Research Institute.
- COMPLETED
- Registry status
- 25 participants
- Enrollment target
Study Summary
The overall goal of this study is to enroll pregnant women with type 1 diabetes and follow their glycemic outcomes prospectively throughout pregnancy and into the post-partum period. The investigators anticipate that when compared to subjects using an Artificial pancreas system (AP) as part of a future protocol, this comparator group of subjects undergoing usual care will exhibit less time in target continuous glucose monitoring (CGM) glucose range defined as 63-140 mg/dL and an increased duration of hypoglycemia with CGM glucose \<63 mg/dL.
Primary Outcome
Time in range defined as 63-140 mg/dL as determined by CGM analysis
Interventions
- DEVICE Dexcom G6 CGM
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2018-11-13 |
| Est. Completion | 2021-06-09 |
What the finished NCT03761615 record still lists
NCT03761615 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 25 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Dexcom G6 CGM is the first listed.
NCT03761615 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03761615 about?
NCT03761615 is a clinical study titled "Longitudinal Observation of Insulin Requirements and Sensor Use in Pregnancy". The overall goal of this study is to enroll pregnant women with type 1 diabetes and follow their glycemic outcomes prospectively throughout pregnancy and into the post-partum period. The investigators anticipate that when compared to subjects using an Artificial pancreas system (AP) as part of a fut...
What is the current status of trial NCT03761615?
This trial is currently completed. The enrollment target is 25 participants. The study started on 2018-11-13. Estimated completion is 2021-06-09.
What interventions are being tested in trial NCT03761615?
The interventions under investigation include: Dexcom G6 CGM (DEVICE).
Who is sponsoring clinical trial NCT03761615?
This trial is sponsored by Sansum Diabetes Research Institute, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI